Evotec will receive a $10 million milestone payment as a kidney cancer trial has got underway.  Bristol Myers Squibb has launched its Phase I clinical study evaluating CELMoD agent BMS-986506, a cereblon E3 ligase modulator, in clear cell renal cell carcinoma, the most common form of kidney cancer.   The first-in-human study brings into the clinic a novel CELMoD or ‘molecular glue’ candidate, jointly generated […]